Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,488.20GBp
18 May 2018
Change (% chg)

-2.20 (-0.15%)
Prev Close
1,490.40
Open
1,487.00
Day's High
1,497.80
Day's Low
1,481.60
Volume
8,969,969
Avg. Vol
9,187,609
52-wk High
1,724.50
52-wk Low
1,235.20

Latest Key Developments (Source: Significant Developments)

GlaxoSmithKline Says ViiV Granted EU Marketing Authorisation For Juluca
Monday, 21 May 2018 

May 21 (Reuters) - GlaxoSmithKline PLC ::VIIV GRANTED EU MARKETING AUTHORISATION FOR JULUCA.VIIV HEALTHCARE RECEIVES EU MARKETING AUTHORISATION FOR JULUCA FIRST 2-DRUG REGIMEN, ONCE-DAILY, SINGLE-PILL FOR TREATMENT OF HIV.  Full Article

GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control
Monday, 21 May 2018 

May 21 (Reuters) - GlaxoSmithKline PLC ::NUCALA (MEPOLIZUMAB) STUDY REPORTS LONG-TERM SAFETY DATA, CONSISTENT EXACERBATION REDUCTION AND IMPROVED ASTHMA CONTROL.NEW STUDY SHOWED ONE THIRD OF PATIENTS HAD NO EXACERBATIONS ON LONG-TERM TREATMENT WITH NUCALA.  Full Article

GlaxoSmithKline CFO Simon Dingemans To Retire From Company
Wednesday, 9 May 2018 

May 9 (Reuters) - GlaxoSmithKline PLC ::SIMON DINGEMANS, CHIEF FINANCIAL OFFICER (CFO), GSK, HAS INFORMED BOARD OF HIS INTENTION TO RETIRE FROM COMPANY.BOARD WILL NOW CONDUCT A THOROUGH GLOBAL SEARCH BOTH INTERNALLY AND EXTERNALLY TO IDENTIFY A SUCCESSOR..  Full Article

GSK New R&D Head Barron Says Work To Do To Translate DPU Research Into Drugs
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Glaxosmithkline ::NEW RESEARCH AND DEVELOPMENT HEAD BARRON SAYS WORK TO DO TO TRANSLATE RESEARCH AT DPU UNITS INTO DRUGS.  Full Article

GSK Expecting Shingrix Sales For Year To Be Above 400 Million Stg
Wednesday, 25 Apr 2018 

April 25 (Reuters) - GlaxoSmithKline ::CFO SAYS EXPECTING SHINGRIX SALES FOR YEAR TO BE AT THE SAME RATE AS IN Q1, OR 400 MILLION STG+ FOR 2018.  Full Article

Glaxosmithkline Says FDA Approves Expanded Indication For Trelegy Ellipta In The U.S.
Tuesday, 24 Apr 2018 

April 24 (Reuters) - GlaxoSmithKline ::FDA APPROVED EXPANDED INDICATION FOR TRELEGY ELLIPTA IN THE U.S. FOR TREATMENT OF PATIENTS WITH COPD.  Full Article

GSK To Transfer Rare Disease Gene Therapy Portfolio To Orchard Therapeutics
Thursday, 12 Apr 2018 

April 12 (Reuters) - GlaxoSmithKline PLC ::GSK SIGNS STRATEGIC AGREEMENT TO TRANSFER RARE DISEASE GENE THERAPY PORTFOLIO TO ORCHARD THERAPEUTICS.GSK TAKES 19.9 PCT EQUITY STAKE IN ORCHARD AND SEAT ON BOARD.GSK TO RECEIVE FINANCIAL CONSIDERATIONS IN FORM OF ROYALTIES AND COMMERCIAL MILESTONE PAYMENTS RELATED TO ACQUIRED PORTFOLIO.BOTH COS AGREED TO A TRANSITION PERIOD DURING WHICH GSK WILL CONTINUE TO CONDUCT CERTAIN ACTIVITIES THROUGH TO END OF 2018.ORCHARD TO ASSUME OBLIGATIONS ARISING FROM GSK'S 2010 COLLABORATION AGREEMENT WITH OSPEDALE SAN RAFFAELE, FONDAZIONE TELETHON.ORCHARD TO ALSO ASSUME ALL OBLIGATIONS ARISING FROM GSK'S COLLABORATION AGREEMENT WITH MOLMED.  Full Article

GlaxoSmithKline Inc Says Trelegy Ellipta Approved In Canada
Thursday, 5 Apr 2018 

April 5 (Reuters) - GlaxoSmithKline Inc::TRELEGY ELLIPTA APPROVED IN CANADA AS FIRST INHALER FOR LONG-TERM, ONCE DAILY TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE .TRELEGY ELLIPTA AVAILABILITY IS EXPECTED JUNE 2018.  Full Article

GSK Receives FDA Approval For Expanded Indication For Fluarix
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Glaxosmithkline Plc ::GSK RECEIVES FDA APPROVAL FOR EXPANDED INDICATION FOR FLUARIX® QUADRIVALENT (INFLUENZA VACCINE) FOR PERSONS 6 MONTHS AND OLDER.  Full Article

GSK CEO Says No Expected Dividend Increase In Near Term
Wednesday, 10 Jan 2018 

Jan 9 (Reuters) - Glaxosmithkline Plc ::GSK CEO SAYS WILL TAKE TIME TO BUILD REIMBURSEMENT FOR SHINGRIX SHINGLES VACCINE.GSK CEO SAYS HAS NO DOUBT SHINGRIX CAN BE COMPANY'S MOST LUCRATIVE VACCINE.GSK CEO SAYS NO CHANGE TO DIVIDEND POLICY LAID OUT LAST YEAR.GSK CEO SAYS NO EXPECTED DIVIDEND INCREASE IN NEAR TERM.GSK CEO SAYS HAVING A LOOK AT PFIZER CONSUMER BUSINESS; WE DON'T NEED IT, WOULDN'T OVERPAY FOR IT.  Full Article

Regulators flag possible birth defect link to GSK's HIV drug

LONDON U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.